• KOL
    • KOLs Community
    • Heart
    • Heart Failure
    • Greegg C Fonarow
    • Greegg C Fonarow

      Greegg C Fonarow

      Division of Cardiology, Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, United States | Division of Cardiology, University of California ...

       

       

      KOL Resume for Greegg C Fonarow

      Year
      2022

      Division of Cardiology, Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, United States

      Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan UCLA Medical Center, Los Angeles, CA 90095, USA.

      Ahmanson‐UCLA Cardiomyopathy Center, University of California, Los Angeles, CA, USA

      Associate Editor for Health Care Quality and Guidelines, JAMA Cardiology

      2021

      Division of Cardiology, University of California, Los Angeles (G.C.F.).

      Ahmanson-UCLA Cardiomyopathy Center, University of California Los Angeles, Los Angeles

      Associate Section Editor, JAMA Cardiology

       

       

      Greegg C Fonarow: Influence Statistics

      Sample of concepts for which Greegg C Fonarow is among the top experts in the world.
      Concept World rank
      guidelineshf program #1
      guidelines program #1
      standard protein diet #1
      15381 patients #1
      outcomes academics #1
      nyha class kccqos #1
      60 90 discharge #1
      hospitals dtn ais #1
      performance management strategies #1
      ccs discharge #1
      bun bnp #1
      incident hf octogenarians #1
      gdmt hospitalization #1
      hhf patients dm #1
      adequate proxy #1
      emotional wellbeing caregivers #1
      readmission hazard #1
      95 adjusted #1
      adherence performance measures #1
      hfpef discharge #1
      patients ischemic hf #1
      hf registry #1
      heart failure readmission #1
      failure diabetes #1
      adherence heart #1
      improvement icd #1
      new discharge prescriptions #1
      137±30 #1
      adhere #1
      adhere medicare beneficiaries #1
      postdischarge follow‐up #1
      optimizehf organized program #1
      40 sbp #1
      ehr hf quality #1
      ckd hospital #1
      antagonists beta #1
      patients alda #1
      hospital white patients #1
      starting doses enalapril #1
      vhr ascvd patients #1
      n2507 #1
      quality heart #1
      gwtgafib #1
      gwtghf #1
      aceibbalda #1
      varying risk profiles #1
      failure hospital #1
      ems hispanic americans #1
      esrd heart failure #1
      aceisarbs #1

       

      Prominent publications by Greegg C Fonarow

      KOL-Index: 22693

      CONTEXT: The association between systolic blood pressure (SBP) at admission, clinical characteristics, and outcomes in patients hospitalized for heart failure who have reduced or relatively preserved systolic function has not been well studied.

      OBJECTIVE: To evaluate the relationship between SBP at admission, clinical profile, and outcomes in patients hospitalized for acute heart failure.

      DESIGN, SETTING, AND PATIENTS: Cohort study using data from the Organized Program to Initiate ...

      Known for Heart Failure | Clinical Characteristics | Admission Patients | Systolic Blood Pressure | Mm Hg
      KOL-Index: 20520

      Importance: Antithrombotic therapies are known to prevent stroke for patients with atrial fibrillation (AF) but are often underused in community practice.

      Objectives: To examine the prevalence of patients with acute ischemic stroke with known history of AF who were not receiving guideline-recommended antithrombotic treatment before stroke and to determine the association of preceding antithrombotic therapy with stroke severity and in-hospital outcomes.

      Design, Setting, and Participants: ...

      Known for Antithrombotic Treatment | Acute Ischemic Stroke | Atrial Fibrillation | Therapeutic Warfarin | Hospital Outcomes
      KOL-Index: 20318

      OBJECTIVES: This study sought to determine the association of chronic kidney disease (CKD) with in-hospital outcomes of transcatheter aortic valve replacement (TAVR).

      BACKGROUND: CKD is a known independent risk factor for worse outcomes after surgical aortic valve replacement (SAVR). However, data on outcomes of patients with CKD undergoing TAVR are limited, especially in those on chronic dialysis.

      METHODS: The authors used data from the 2012 to 2014 National Inpatient Sample database to ...

      Known for Patients Ckd | Chronic Kidney | Aortic Valve | Hospital Outcomes | Replacement Tavr
      KOL-Index: 20035

      IMPORTANCE: The benefits of intravenous tissue plasminogen activator (tPA) in patients with acute ischemic stroke (AIS) are time dependent and guidelines recommend a door-to-needle (DTN) time of 60 minutes or less. However, studies have found that less than 30% of US patients are treated within this time window.

      TARGET: Stroke was designed as a national quality improvement initiative to improve DTN times for tPA administration in patients with AIS.

      OBJECTIVES: To evaluate DTN times for ...

      Known for 60 Minutes | Plasminogen Activator | Patients Ais | Improvement Initiative | Postintervention Period
      KOL-Index: 19811

      IMPORTANCE: The benefits of cardiac resynchronization therapy (CRT) in clinical trials were greater among patients with left bundle-branch block (LBBB) or longer QRS duration.

      OBJECTIVE: To measure associations between QRS duration and morphology and outcomes among patients receiving a CRT defibrillator (CRT-D) in clinical practice.

      DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study of Medicare beneficiaries in the National Cardiovascular Data Registry's ICD Registry between ...

      Known for Qrs Duration | Heart Failure | Patients Lbbb | Resynchronization Therapy | Branch Block
      KOL-Index: 19058

      AIMS: Signs and symptoms of congestion are the most common cause for hospitalization for heart failure (HHF). The clinical course and prognostic value of congestion during HHF has not been systemically characterized.

      METHODS AND RESULTS: A post hoc analysis was performed of the placebo group (n = 2061) of the EVEREST trial, which enrolled patients within 48 h of admission (median ~24 h) for worsening HF with an EF ≤ 40% and two or more signs or symptoms of fluid overload [dyspnoea, ...

      Known for Everest Trial | Heart Failure | Patients Ccs | Signs Symptoms | Reduced Ejection Fraction
      KOL-Index: 17405

      Importance: Although non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used to prevent thromboembolic disease, there are limited data on NOAC-related intracerebral hemorrhage (ICH).

      Objective: To assess the association between preceding oral anticoagulant use (warfarin, NOACs, and no oral anticoagulants [OACs]) and in-hospital mortality among patients with ICH.

      Design, Setting, and Participants: Retrospective cohort study of 141 311 patients with ICH admitted from ...

      Known for Oral Anticoagulants | Warfarin Patients | Hospital Mortality | Intracerebral Hemorrhage | Noacs Lower Risk
      KOL-Index: 17324

      IMPORTANCE: Heart failure (HF) guidelines recognize that a subset of patients with HF and preserved left ventricular ejection fraction (LVEF) previously had reduced LVEF but experienced improvement or recovery in LVEF. However, data on these patients are limited.

      OBJECTIVE: To investigate the characteristics and outcomes of adult outpatients with HF and improved or recovered ejection fraction (HFrecEF).

      DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study (inception period, ...

      Known for Patients Hf | Heart Failure | Ejection Fraction | Characteristics Outcomes | Death Cardiovascular Hospitalization
      KOL-Index: 16895

      Importance: There are concerns whether percutaneous coronary intervention (PCI) at centers without on-site cardiac surgery is safe outside of a tightly regulated research environment.

      Objective: To analyze the outcomes and temporal trends of inpatient PCI at centers without on-site cardiac surgery in an unselected and nationally representative population of the United States.

      Design, Setting, and Participants: A national inpatient sample (N = 6 912 232) was used to identify patients who ...

      Known for United States | Centers Site | Temporal Trends | Cardiac Surgery | Percutaneous Coronary
      KOL-Index: 16696

      CONTEXT: Intravenous tissue plasminogen activator (tPA) is known to improve outcomes in ischemic stroke; however, patients receiving long-term chronic warfarin therapy may face an increased risk for intracranial hemorrhage when treated with tPA. Although current guidelines endorse administering intravenous tPA to warfarin-treated patients if their international normalized ratio (INR) is 1.7 or lower, there are few data on safety of intravenous tPA in warfarin-treated patients in clinical ...

      Known for Ischemic Stroke | Intracranial Hemorrhage | Intravenous Tpa | Tissue Plasminogen | Warfarintreated Patients
      KOL-Index: 16654

      Importance: Public reporting of hospitals' 30-day risk-standardized readmission rates following heart failure hospitalization and the financial penalization of hospitals with higher rates have been associated with a reduction in 30-day readmissions but have raised concerns regarding the potential for unintended consequences.

      Objective: To examine the association of the Hospital Readmissions Reduction Program (HRRP) with readmission and mortality outcomes among patients hospitalized with ...

      Known for Heart Failure | Hrrp Implementation | Readmissions Reduction | Mortality Outcomes | Fee Service
      KOL-Index: 16638

      Heart failure (HF) affects >5 million patients in the United States, and its prevalence is increasing every year. Despite the compelling scientific evidence that angiotensin-converting enzyme inhibitors and beta-blockers reduce hospitalizations and mortality rates in patients with HF, these lifesaving therapies continue to be underused. Several studies in a variety of clinical settings have documented that a significant proportion of eligible patients with HF are not receiving treatment ...

      Known for Organized Program | Heart Failure | Hospitalized Patients | Lifesaving Treatment | Hospital Discharge
      KOL-Index: 16463

      IMPORTANCE: The angiotensin receptor neprilysin inhibitor sacubitril/valsartan was associated with a reduction in cardiovascular mortality, all-cause mortality, and hospitalizations compared with enalapril. Sacubitril/valsartan has been approved for use in heart failure (HF) with reduced ejection fraction in the United States and cost has been suggested as 1 factor that will influence the use of this agent.

      OBJECTIVE: To estimate the cost-effectiveness of sacubitril/valsartan vs ...

      Known for Reduced Ejection Fraction | Heart Failure | Sacubitril Valsartan Enalapril | United States | Sensitivity Analyses
      KOL-Index: 16340

      OBJECTIVES: This study sought to assess the effect of angiotensin-converting enzyme (ACE) inhibitors and beta-blockers on all-cause mortality in patients with left ventricular (LV) systolic dysfunction according to gender, race, and the presence of diabetes.

      BACKGROUND: Major randomized clinical trials have established that ACE inhibitors and beta-blockers have life-saving benefits in patients with LV systolic dysfunction. Most patients enrolled in these trials were Caucasian men. ...

      Known for Enzyme Inhibitors | Systolic Dysfunction | Betablockers Patients | Diabetic Status | Diabetes Women
      KOL-Index: 16220

      BACKGROUND: Older women presenting with ST-segment elevation myocardial infarction (STEMI) are less likely to receive revascularization and have worse outcomes relative to their male counterparts.

      OBJECTIVES: This study sought to determine temporal trends and sex differences in revascularization and in-hospital outcomes of younger patients with STEMI.

      METHODS: We used the 2004 to 2011 Nationwide Inpatient Sample databases to identify all patients age 18 to 59 years hospitalized with ...

      Known for Temporal Trends | United States | Younger Women | Stemi Hospital | Myocardial Infarction

      Key People For Heart Failure

      Top KOLs in the world
      #1
      John J J V McMurray
      heart failure myocardial infarction atrial fibrillation
      #2
      John George Franklin Cleland
      heart failure patients hf atrial fibrillation
      #3
      Stephan D Anker
      heart failure iron deficiency cardiac cachexia
      #4
      Greegg C Fonarow
      heart failure atrial fibrillation united states
      #5
      Karl B Swedberg
      heart failure reduced ejection fraction myocardial infarction
      #6
      Piotr P Ponikowski
      heart failure iron deficiency reduced ejection fraction

      Greegg C Fonarow:Expert Impact

      Concepts for whichGreegg C Fonarowhas direct influence:Heart failure,  Atrial fibrillation,  United states,  Patients heart failure,  Ischemic stroke,  Heart failure hf,  Myocardial infarction,  Patients hf.

      Greegg C Fonarow:KOL impact

      Concepts related to the work of other authors for whichfor which Greegg C Fonarow has influence:Heart failure,  Atrial fibrillation,  Myocardial infarction,  Cardiovascular disease,  Ischemic stroke,  Patients hf,  Preserved ejection fraction.


       

      Tools

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile


      Division of Cardiology, Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, United States | Division of Cardiology, University of California Los Angeles, Los Angeles, CA. | Ahmanson-UCLA Cardiomyopathy Center, Ronald

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.